- The disease
- Breast cancer-related lymphedema (BCRL) is a chronic condition in which damage to the lymphatic system during breast cancer treatment causes fluid to accumulate in the arm, causing swelling, discomfort, and reduced function. It is estimated to affect a meaningful proportion of breast cancer survivors, though estimates vary across studies. The condition can develop months to years after treatment and, once established, is difficult to reverse. Early identification of fluid accumulation before visible swelling appears is therefore a clinical priority.
- What the asset is trying to do
- SOZO is a medical device that uses bioimpedance spectroscopy (BIS) to measure how electrical signals at multiple frequencies pass through body tissues, providing a quantitative index of extracellular fluid (fluid outside cells) in the limb. The device generates an L-Dex score that, according to ImpediMed, can detect fluid changes up to ten months before visible swelling develops. This differs from traditional tape-measure assessment, which can only detect swelling after it becomes physically apparent.
- What the trial is measuring, and why it matters
- The lead active trial (NCT03292198, Subclinical Lymphedema Treatment Study) is evaluating an intervention approach in patients identified by BIS as having subclinical (pre-visible) lymphedema. The PREVENT trial (NCT02167659, completed, n=1,201 per ClinicalTrials.gov NCT02167659) compared a BIS-guided compression intervention against tape-measure surveillance for lymphedema prevention. These studies collectively examine whether earlier detection via BIS translates into better patient outcomes, including progression to clinical lymphedema.
- Efficacy benchmarks in this setting
- In the completed PREVENT trial (NCT02167659, n=1,201), the BIS-guided intervention arm showed a lower rate of progression to clinical lymphedema compared with the tape-measure arm, per the published trial record on ClinicalTrials.gov; full outcome data should be sourced from the primary publication for precise figures. For context on approved treatment benchmarks in established BCRL, complete decongestive therapy (CDT) remains the standard of care, though published response rates vary by outcome measure and study design and cannot be directly compared to a diagnostic device's performance metrics. This asset's role is detection rather than treatment, so efficacy benchmarks for therapeutic interventions in the same setting are not directly comparable.
- Commercial context